This website uses cookies

This website uses cookies to ensure you get the best experience. By using our website, you agree to our Privacy Policy

International In-house Counsel Journal logoInternational In-house Counsel Journal logo
Back to library search

Client Centricity & the In-House Lawyer

Abstract

The practice of law has evolved, particularly given the advent of significant technological advances, enhancements, and the evolving nature of the business world. Twenty years ago, first year law students’ core curriculum involved legal writing and legal research, which was, in essence, how to use the law library to find cases, statutes, and law review articles in their corresponding shelved book and then “Sheperdize” the legal authorities to confirm case precedent and validity. Twenty to thirty years ago, major corporations and companies relied on outside counsel and law firms for their legal advice -- and did not have in-house attorneys beyond the General Counsel role. The change was an increasing awareness and recognition of the intrinsic value of in-house lawyers: here are legal experts that become embedded within the many facets and dimensions of the business, and, who can serve as a gatekeeper for the myriad of legal, ethical, and financial rules and obligations of the company. In-house lawyers serve an important role in advising and leading their client, “the company”. For instance, when an in-house attorney is involved in litigation or conducting an internal investigation, it is both ethically and professionally necessary to give the Upjohn warning -- clearly identifying the communications between the company counsel and employees as privileged – but that privilege belongs to the company as client, not the individual employees.

Author

Portrait image of Kari Loeser
Kari Loeser
Senior Counsel, Jazz Pharmaceuticals , USA

Kari Loeser, Esq. is senior corporate counsel and senior director in the Legal & Compliance department at Jazz Pharmaceuticals plc. In this role, she oversees and conducts all US and global internal investigations and has advised client groups on a variety of legal and compliance matters pertaining to sales, marketing, and promotional matters for the Oncology portfolio; medical affairs including clinical/research, publications, and health economic outcomes research; and managed care and reimbursement activities. She also managed a team responsible for federal/state aggregate spend reporting (transparency) and compliance field monitoring. Prior to Jazz, Kari worked in medical affairs and healthcare compliance at Genentech, a member of the Roche Group. She has published various articles and a book chapter on E-Health and Ethics, and she has presented at various conferences, including the AHLA-HCCA Fraud and Abuse Conference. She is currently authoring a book chapter in CANCER POLICY: PHARMACEUTICAL SAFETY entitled “Anatomy of Risk Evaluation and Mitigation Strategies (REMS)” by Springer Publishing (Germany) with a proposed publication and release date in 2017. She is a licensed attorney, and is certified in Healthcare Compliance. She received her JD from DePaul University College of Law, and her BA with Honors from the University of Iowa.

Company

Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. Our focus is on sleep, hematology/oncology and other areas in which our unique approach may be able to address significant treatment gaps.

Related Papers

Managing Compliance Risk in a COVID and Post-COVID World
Managing risk can be complicated in the best of times, and the challenges associated with risk management become even greater when combined with the tremendous disruption caused by a global...Read more
Portrait image of Fabiana Lacerca-Allen
Fabiana Lacerca-Allen
Chief Compliance Officer, Cipla, USA
Portrait image of Tatiyana Akers
Tatiyana Akers
Associate Director, Compliance, Aimmune Therapeutics, USA
Portrait image of Laura Hamm
Laura Hamm
Sr. Director, Corporate Compliance, Aimmune Therapeutics, USA
Portrait image of Brenda Crabtree
Brenda Crabtree
Director, Compliance Auditing and Monitoring, Aimmune Therapeutics, USA
Paper Title International Pharma Congresses during Covid-19
Pharmaceutical congresses and conferences are one of the preferred resources for doctors to learn about new research, treatments and indications . Such congresses in 2020 have become ‘virtual’ in response...Read more
Portrait image of Geraldine Benjamin
Geraldine Benjamin
English Solicitor, Bailhache Labesse Trustees, UK
Making it Stick: How to Provide Legal Advice that Influences Business Decisions
As attorneys, determining the most risk-averse legal advice to give to our business partners often comes naturally. After all, we have both academic and professional experience in considering legal questions. But...Read more
Portrait image of Joshua Axelrod
Joshua Axelrod
Brand Counsel, Celgene Corporation, USA
A Glance at Some of the Challenges of the GC Role in Pharma
In the heavily regulated environment in which pharmaceutical companies operate, success is defined by ensuring corporate compliance with disparate laws and regulations without fettering the creativity and innovation on which...Read more
Portrait image of Galit Gonen
Galit Gonen
Senior Vice President & General Counsel for Teva Europe, Teva Pharmaceuticals, UK